Level Bio (LEVBIO) Stock Overview
Manufactures and distributes cutting-edge and diagnostic solutions in the Nordic region and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
LEVBIO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.
Read full narrativeLevel Bio AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.28 |
| 52 Week High | SEK 0 |
| 52 Week Low | SEK 0 |
| Beta | 1.29 |
| 1 Month Change | -20.11% |
| 3 Month Change | -19.19% |
| 1 Year Change | -30.50% |
| 3 Year Change | -56.15% |
| 5 Year Change | -82.63% |
| Change since IPO | -97.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| LEVBIO | SE Life Sciences | SE Market | |
|---|---|---|---|
| 7D | -18.2% | -2.0% | 3.7% |
| 1Y | -30.5% | -18.1% | 15.7% |
Return vs Industry: LEVBIO underperformed the Swedish Life Sciences industry which returned -18.1% over the past year.
Return vs Market: LEVBIO underperformed the Swedish Market which returned 15.7% over the past year.
Price Volatility
| LEVBIO volatility | |
|---|---|
| LEVBIO Average Weekly Movement | 24.5% |
| Life Sciences Industry Average Movement | 6.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in SE Market | 13.1% |
| 10% least volatile stocks in SE Market | 3.7% |
Stable Share Price: LEVBIO's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: LEVBIO's weekly volatility (24%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 10 | Joakim Granemo | levelbio.se |
Level Bio AB (publ) manufactures and distributes cutting-edge and diagnostic solutions in the Nordic region and internationally. It develops and manufactures diagnostic kits for the clinical market, as well as act as a distributor and full service partner to molecular biology labs in the Nordics. The company was formerly known as AlphaHelix Molecular Diagnostics AB (publ) and changed its name to Level Bio AB (publ) in May 2024.
Level Bio AB (publ) Fundamentals Summary
| LEVBIO fundamental statistics | |
|---|---|
| Market cap | SEK 19.01m |
| Earnings (TTM) | -SEK 2.87m |
| Revenue (TTM) | SEK 33.51m |
Is LEVBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LEVBIO income statement (TTM) | |
|---|---|
| Revenue | SEK 33.51m |
| Cost of Revenue | SEK 15.55m |
| Gross Profit | SEK 17.95m |
| Other Expenses | SEK 20.82m |
| Earnings | -SEK 2.87m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.042 |
| Gross Margin | 53.58% |
| Net Profit Margin | -8.57% |
| Debt/Equity Ratio | 0% |
How did LEVBIO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/07 13:18 |
| End of Day Share Price | 2026/05/07 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Level Bio AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.